Document:

EX-10.8

 Exhibit 10.8 

DESIGN THERAPEUTICS, INC. 

NON-EMPLOYEE DIRECTOR COMPENSATION
POLICY 
 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or
consultant to Design Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service upon and following the date of the underwriting agreement between the Company and the underwriters managing the initial public offering of the
Company’s common stock (the “Common Stock”), pursuant to which the Common Stock is priced in such initial public offering (the “Effective Date”). An Eligible Director may decline all or any
portion of his or her compensation by giving notice to the Company prior to the date cash may be paid or equity awards are to be granted, as the case may be. This policy is effective as of the Effective Date and may be amended at any time in the
sole discretion of the Board or the Compensation Committee of the Board. 
 Annual Cash Compensation 

The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of
each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal quarter, with the pro-rated amount paid on the last day of the first fiscal quarter in which the Eligible Director
provides the service and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. 
  

	1.	 Annual Board Service Retainer: 

 

	 	a.	 All Eligible Directors: $35,000 

 

	 	b.	 Chair of the Board Service Retainer (in addition to Eligible Director Service Retainer): $30,000

  

	2.	 Annual Committee Chair Service Retainer: 

 

	 	a.	 Chair of the Audit Committee: $15,000 

 

	 	b.	 Chair of the Compensation Committee: $10,000 

 

	 	c.	 Chair of the Nominating and Corporate Governance Committee: $8,000 

 

	 	d.	 Chair of the Research & Development Committee: $15,000 

 

	3.	 Annual Committee Member Service Retainer (not applicable to Committee Chairs): 

 

	 	a.	 Member of the Audit Committee: $7,500 

 

	 	b.	 Member of the Compensation Committee: $5,000 

 

	 	c.	 Member of the Nominating and Corporate Governance Committee: $4,000 

 

	 	b.	 Member of the Research & Development Committee: $7,500 

  
 1. 

 Equity Compensation 

The equity compensation set forth below will be granted under the Company’s 2021 Equity Incentive Plan (the “Plan”), subject to
the approval of the Plan by the Company’s stockholders. All stock options granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the
underlying Common Stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan). 

1. Post-IPO Initial Grant: For each Eligible Director who is first elected or appointed to the Board following
the Effective Date, on the date of such Eligible Director’s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and
without further action by the Board or the Compensation Committee of the Board, granted a stock option to purchase 30,000 shares of Common Stock (the “Post-IPO Initial
Grant”). The shares subject to each Post-IPO Initial Grant will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the
date of grant, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan). 

2. Annual Grant: On the date of each annual stockholder meeting of the Company held after the Effective Date (an “Annual
Meeting”), each Eligible Director who continues to serve as a non-employee member of the Board following such Annual Meeting will be automatically, and without further action by the Board or the
Compensation Committee of the Board, granted a stock option to purchase 15,000 shares of Common Stock (the “Annual Grant”). If an Eligible Director was elected or appointed for the first time to be an Eligible Director after
the Effective Date and prior to an Annual Meeting, then the Eligible Director will be granted a prorated Annual Grant on the date of the Eligible Director’s election or appointment (the “Prorated Annual Grant”) that
will be subject to the number of shares of Common Stock equal to 15,000 multiplied by a fraction (the numerator of which is equal to (i) 12 minus (ii) the number of completed months since the most recent Annual Meeting as of the
Eligible Director’s date of election or appointment, and the denominator of which is 12), with the resulting number of shares rounded down to the nearest whole share. The shares subject to the Annual Grant or Prorated Annual Grant will vest in
equal monthly installments over the 12 months following the date of grant, provided that the Annual Grant will in any case be fully vested on the date of Company’s next Annual Meeting, subject to the Eligible Director’s Continuous Service
through such vesting date; provided, further, that the shares subject to the Annual Grant or Prorated Annual Grant will vest in full upon a Change in Control. 

Non-Employee Director Compensation Limit 

Notwithstanding the foregoing, the aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director (as defined in the Plan) shall in no event exceed the limits set forth in the Plan. 

  
 2.EX-10.12

 Exhibit 10.12 

DESIGN THERAPEUTICS, INC. 

CONSULTING AGREEMENT 

THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of December 27, 2017, by and between DESIGN
THERAPEUTICS, INC., a Delaware corporation having its principal place of business located at 991C Lomas Santa Fe #436, Solana Beach, CA 92075 (collectively with its affiliates, “Company”), and ASEEM Z. ANSARI, PhD
(“Consultant”). 
 The Company desires to retain Consultant as an independent contractor to perform consulting
services for the Company and Consultant is willing to perform such services, on the terms described below. 
 AGREEMENT 

In consideration of the mutual promises contained herein, the parties agree as follows: 

1. Services and Compensation. Consultant agrees to perform for the Company the services described in Exhibit A as requested by
the Company from time to time (the “Services”), and the Company agrees to pay Consultant the compensation described in Exhibit A for Consultant’s performance of the Services. If not specified on Exhibit A,
the scope, timing, duration, and site of performance of said Services shall be mutually and reasonably agreed to by the Company and Consultant and are subject to change upon the written agreement of both parties. Consultant will make reasonable,
good faith efforts to provide the Services in a timely and professional manner consistent with industry practices. 
 2. Confidentiality.

 2.1 Definitions. “Confidential Information” means all data, information, technology, samples
and specimens relating to the Company or its plans, products, product concepts, technologies, business, financial, marketing, research, non-clinical, clinical or regulatory affairs, manufacturing processes and
procedures, or those of any other third party, from whom the Company receives information on a confidential basis, whether written, graphic or oral, furnished to Consultant by or on behalf of the Company, either directly or indirectly, or obtained
or observed by Consultant while providing services hereunder, and the Services to be provided by Consultant hereunder. Confidential Information does not include (i) information that is now in the public domain or subsequently enters the public
domain and is generally available without fault on the part of Consultant; (ii) information that is presently known by Consultant from Consultant’s own sources as evidenced by Consultant’s prior written records; or
(iii) information disclosed to Consultant by a third party legally and contractually entitled to make such disclosures. 
 2.2
Nonuse and Nondisclosure. Consultant will not, during or subsequent to the term of this Agreement, (i) use the Confidential Information for any purpose whatsoever other than the performance of the Services on behalf of the Company or
(ii) disclose the Confidential Information to any third party. Consultant agrees that, as between the Company and Consultant, all Confidential Information will remain the sole property of the Company. Consultant also agrees to take all
necessary and reasonable precautions to prevent any unauthorized disclosure of such 

  
 1 of 8 

 
Confidential Information. Without the Company’s prior written approval, Consultant may disclose the existence, but not the terms, of this Agreement to third parties. Anything to the contrary
notwithstanding, Consultant may also disclose Confidential Information to the extent such disclosure is required by a court of competent jurisdiction and provided that Consultant promptly notifies the Company of such requirement. Consultant
acknowledges that the use or disclosure of Confidential Information without the Company’s express written permission will cause the Company irreparable harm and that any material breach or threatened material breach of this Agreement by
Consultant will entitle the Company to seek injunctive relief and reasonable attorneys’ fees, in addition to any other legal remedies available to it, in any court of competent jurisdiction. 

2.3. Third Party Confidential Information. Consultant recognizes that the Company has received and in the future may receive from third
parties, their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. Consultant agrees that, during the Term of this
Agreement and thereafter, Consultant owes the Company and such third parties a duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or entity or to use it except as
necessary in carrying out the Services for the Company consistent with the Company’s agreement with such third party, unless otherwise authorized by such third party. 

2.3 Return of Materials. At any time upon the Company’s request, Consultant will deliver to the Company all of the Company’s
property, equipment and documents, together with all copies thereof, that were previously given to Consultant, including but not limited to all electronically stored confidential and/or nonpublic information, passwords to access such property, or
Confidential Information that Consultant may have in Consultant’s possession or control, and Consultant agrees to certify in writing that Consultant has fully complied with this obligation. 

3. Ownership. 
 3.1
Assignment. Consultant agrees that all copyrights and copyrightable material, notes, records, drawings, designs, inventions, ideas, discoveries, enhancements, modifications, know-how, improvements,
developments, discoveries, trade secrets’ data and information of every kind and description conceived, generated, made, discovered, developed or reduced to practice by Consultant, solely or in collaboration with others, during the Term and in
the course of performing Services under this Agreement (collectively, “Inventions”), are, as between the Company and Consultant, the sole and exclusive property of the Company. Consultant agrees to disclose such Inventions promptly
to the Company and hereby assigns, and agrees to assign, all of Consultant’s right, title and interest in and to any such Inventions promptly to the Company without royalty or any other consideration and to execute all applications, assignments
or other instruments reasonably requested by the Company in order for the Company to establish the Company’s ownership of such Inventions and to obtain whatever protection for such Inventions, including copyright and patent rights in any and
all countries on such Inventions as the Company shall determine. 

  
 2 of 8 

 3.2 Further Assurances. Consultant agrees to reasonably assist the Company, or its
designee, to secure the Company’s rights in Inventions and any copyrights, patents or other intellectual property rights relating to all Inventions in any and all countries, including the disclosure to the Company of all pertinent information
and data with respect to all Inventions, the execution of all applications, specifications, oaths, assignments and all other instruments that the Company may deem necessary in order to apply for and obtain such rights and in order to assign and
convey to the Company, its successors, assigns and nominees the sole and exclusive right, title and interest in and to all Inventions, and any copyrights, patents, or other intellectual property rights relating to all Inventions. Consultant also
agrees that Consultant’s obligation to execute or cause to be executed any such instrument or papers shall continue after the termination of this Agreement. 

3.3 Pre-Existing Materials. Subject to Section 3.1, Consultant agrees that if, in the
course of performing the Services, Consultant incorporates into any Invention developed under this Agreement any pre-existing invention, improvement, development, concept, discovery or other proprietary
information owned by Consultant or in which Consultant has an interest, (i) Consultant will inform the Company, in writing before incorporating such invention, improvement, development, concept, discovery or other proprietary information into
any Invention, and (ii) the Company is hereby granted a nonexclusive, royalty-free, perpetual, irrevocable, worldwide license to make, have made, modify, use and sell such item as part of or in connection with such Invention. Consultant will
not incorporate any invention, improvement, development, concept, discovery or other proprietary information owned by any third party into any Invention without the Company’s prior written permission, including without limitation any
intellectual property of the University of Wisconsin, the Wisconsin Alumni Research Foundation, or that was otherwise funded in whole or in part with federal grants. 

3.4 Attorney-in-Fact. Consultant agrees that, if the
Company is unable because of Consultant’s unavailability, dissolution, mental or physical incapacity, or for any other reason, to secure Consultant’s signature for the purpose of applying for or pursuing any application for any United
States or foreign patents, mask work or copyright registrations covering the Inventions assigned to the Company in Section 3.1, then Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents
as Consultant’s agent and attorney-in-fact, to act for and on Consultant’s behalf to execute and file any such applications and to do all other lawfully
permitted acts only to further the prosecution and issuance of patents, copyright and mask work registrations with the same legal force and effect as if executed by Consultant. 

4. Representations and Warranties. Consultant represents and warrants to the Company that Consultant is legally able to enter into this
Agreement and that Consultant’s execution, delivery and performance of this Agreement will not and does not conflict with any agreement, arrangement or understanding, written or oral, to which Consultant is a party or by which Consultant is
bound.  
 5. Term and Termination. 

5.1 Term. The term of this Agreement (the “Term”) shall commence on the date this Agreement is signed by all
parties hereto (the “Effective Date”), and shall remain in full 

  
 3 of 8 

 
force and effect until the earlier of (i) final completion of the Services or (ii) termination as provided in Section 5.2.  

5.2 Termination. Either party may terminate this Agreement by giving three (3) months prior written notice to the other party. The
Company may terminate this Agreement immediately and without prior notice if Consultant refuses to or is unable to perform the Services or is in breach of any material provision of this Agreement. The Company and Consultant agree that the terms and
conditions of this Agreement, including the Term, shall be subject to an annual review by the Company’s Board of Directors.  

5.3 Survival. Upon termination of this Agreement, all rights and duties of the Company and Consultant toward each other shall cease
except: 
 (a) The Company will pay, within 30 days after the effective date of termination, all amounts owing to
Consultant for Services completed and accepted by the Company prior to the termination date and related expenses, if any, submitted in accordance with the Company’s policies and in accordance with the provisions of Section 1 of this
Agreement; and 
 (b) Sections 2, 3, 4, 5.3, 6, 9, 10.1, and 10.2 will survive termination of this Agreement. 

6. Independent Contractor; Benefits; Taxes. 

6.1 Independent Contractor. It is the expressed intention of the Company and Consultant that Consultant performs the Services as an
independent contractor to the Company, and nothing in this Agreement should be construed to create a partnership, joint venture or employer-employee relationship. Consultant (a) is not the agent of the Company and (b) is not authorized to
make any representation, contract, or commitment on behalf of the Company.  
 6.2 Benefits. The Company and Consultant agree
that Consultant will receive no Company-sponsored benefits from the Company. If Consultant is reclassified by a state or federal agency or court as the Company’s employee, Consultant will become a reclassified employee and will receive no
benefits from the Company, except those mandated by state or federal law, even if by the terms of the Company’s benefit plans or programs of the Company in effect at the time of such reclassification, Consultant would otherwise be eligible for
such benefits.  
 6.3 Taxes and Withholdings. The Company shall not be responsible for paying any federal, state or local
taxes on compensation, and Consultant shall be solely responsible for the payment thereof. The Company may, however, report payments made to Consultant hereunder to tax authorities and shall inform Consultant of such actions. Consultant agrees to
accept exclusive liability for complying with all applicable state and federal laws, including laws governing self-employed individuals, if applicable, such as laws related to payment of taxes, social security, disability, and other contributions
based on fees paid to Consultant under this Agreement. The Company will not withhold or make payments for social security, unemployment insurance or disability insurance contributions, or obtain workers’ compensation insurance on
Consultant’s behalf. Consultant hereby agrees to indemnify and defend the Company against any and all such taxes or contributions, including penalties and interest. Consultant agrees to provide proof of

  
 4 of 8 

 
payment of appropriate taxes on any fees paid to Consultant under this Agreement upon reasonable request of the Company.  

7. Indemnification. Consultant agrees to indemnify and hold harmless the Company and its directors, officers and employees from and
against all claims, demands, losses, damages, liabilities, costs and expenses whatsoever, including without limitation attorneys’ fees and other legal expenses, arising directly or indirectly from or in connection with (i) any grossly
negligent or intentionally wrongful act of Consultant or Consultant’s assistants, employees or agents, (ii) any breach by Consultant or Consultant’s assistants, employees or agents of any of the covenants contained in this Agreement,
(iii) any material failure of Consultant to perform the Services in accordance with all applicable laws, rules and regulations, or (iv) any violation or claimed violation of a third party’s rights resulting in whole or in part from
the Company’s use of the work product of Consultant under this Agreement and for which Consultant deliberately misrepresented to the Company the status of third party rights.  

The Company shall defend, indemnify and hold Consultant harmless from and against any and all claims, demands, losses, damages, liabilities
(including without limitation product liability), settlement amounts, costs and expenses whatsoever (including without limitation reasonable attorneys’ fees and costs and including, without limitation, product liability claims) arising from or
relating to any claim, action or proceeding made or brought against Consultant or the Company as a result of, or associated with, the development, use, manufacture, marketing or sale of products regarding which Consultant has provided Services
unless such liability arises from Consultant’s or Consultant’s assistants’, employees’ or agents’ gross negligence or intentional misconduct. 

8. Nonsolicitation; Non-Disclosure. 

8.1 Nonsolicitation. From the date of this Agreement until 12 months after the termination of this Agreement (the
“Restricted Period”), Consultant will not, without the Company’s prior written consent, directly or indirectly, whether for Consultant’s own account or for the account of any other person, firm, corporation or other
business organization, solicit, entice, persuade, induce or otherwise attempt to influence any person or business who is, or during the period of Consultant’s engagement by the Company was, an employee, consultant, contractor, partner,
supplier, customer or client of the Company or its affiliates to leave or otherwise stop doing business with the Company.  
 8.2 Non-Disclosure. Consultant agrees that without the prior written consent of the Company, Consultant will not intentionally generate any publicity, news release or other announcement concerning the engagement of
Consultant hereunder or the services to be performed by Consultant hereunder or otherwise utilize the name of the Company or any of its affiliates for any advertising or promotional purposes.  

9. Voluntary Nature of Agreement. Consultant acknowledges and agrees that Consultant is executing this Agreement voluntarily and
without any duress or undue influence by the Company or anyone else. Consultant further acknowledges and agrees that Consultant has carefully read this Agreement and has asked any questions needed to understand the terms, consequences and binding
effect of this Agreement and fully understand it to his or her satisfaction. 

  
 5 of 8 

 Finally, Consultant agrees that Consultant has been provided an opportunity to seek the advice of an
attorney of its choice before signing this Agreement.  
 10. Miscellaneous. 

10.1 Governing Law. This Agreement shall be governed by the laws of California without regard to conflicts of law rules.  

10.2 Assignability. Except as otherwise provided in this Agreement, Consultant may not sell, assign or delegate any rights or
obligations under this Agreement.  
 10.3 Entire Agreement. This Agreement constitutes the entire agreement between the
parties with respect to the subject matter of this Agreement and supersedes all prior written and oral agreements between the parties regarding the subject matter of this Agreement.  

10.4 Headings. Headings are used in this Agreement for reference only and shall not be considered when interpreting this Agreement.
 
 10.5 Notices. Any notice or other communication required or permitted by this Agreement to be given to a party shall be in
writing and shall be deemed given if delivered personally or by commercial messenger or courier service, or mailed by U.S. registered or certified mail (return receipt requested), or sent via facsimile (with receipt of confirmation of complete
transmission) to the party at the party’s address or facsimile number written below or at such other address or facsimile number as the party may have previously specified by like notice. If by mail, delivery shall be deemed effective 3
business days after mailing in accordance with this Section 10.5.  
  

			
	If to the Company, to:	 	
		
	Design Therapeutics, Inc.	 	
	 991C Lomas Santa Fe #436
	 	
	Solana Beach, CA 92075	 	
		
	If to Consultant, to:	 	
		
	  
	 	
	  
	 	
	  
	 	

 The address for notice on the signature page to the Agreement or, if no such address is provided, to the last
address of Consultant provided by Consultant to the Company. 
 10.6 Nature of Services. The Company acknowledges that
Consultant’s role is advisory in nature. The Company is therefore free, in its sole discretion to accept, modify, or reject Consultant’s recommendations or any work product resulting from the provision of Services as described herein. The
Company shall be solely responsible for the consequences, direct or indirect, of any such decision by the Company. 

  
 6 of 8 

 10.7 Amendments; Waiver. No modification of or amendment to this Agreement, or any
waiver of any rights under this Agreement, will be effective unless in writing and signed by Consultant and the Company. 
 10.8
Attorneys’ Fees. In any court action at law or equity that is brought by one of the parties to this Agreement to enforce or interpret the provisions of this Agreement, the prevailing party will be entitled to reasonable attorneys’
fees, in addition to any other relief to which that party may be entitled. 
 10.9 Further Assurances. Consultant agrees, upon
request, to execute and deliver any further documents or instruments necessary or desirable to carry out the purposes or intent of this Agreement. 

10.10 Severability. If any provision of this Agreement is found to be illegal or unenforceable, the other provisions shall remain
effective and enforceable to the greatest extent permitted by law. 
 10.11 Counterparts and Facsimiles. This Agreement may be
executed in one or more counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. Facsimile signatures shall be deemed original signatures for all purposes. 

[Signature Page Follows] 

  
 7 of 8 

 DESIGN THERAPEUTICS, INC. 

IN WITNESS WHEREOF, the parties hereto have executed this Consulting Agreement as of the date first written above. 

 

									
	CONSULTANT	 		 	DESIGN THERAPEUTICS, INC.
					
	By:	 	 /s/ Aseem Z. Ansari
	 		 	By:	 	 /s/ Pratik Shah

					
	Name:	 	Aseem Z. Ansari	 		 	Name:	 	Pratik Shah
		 	Consultant	 		 	Title:	 	President and CEO
			
	Address for Notice:	 		 	Address for Notice:
			
	  
	 		 	 991C Lomas Santa Fe #436

	  
	 		 	 Solana Beach, CA 92075

 [SIGNATURE PAGE TO CONSULTING AGREEMENT] 

  
 8 of 8 

 EXHIBIT A 

SERVICES AND COMPENSATION 
  

	1.	 Services. The Services shall include the following operational activities as requested by the
Company:  

  

	 	•	 	 Consulting services regarding molecules that modulate gene expression for human therapeutics, including
potential commercial applications such as assays, etc.  

 The manner and means that Consultant chooses to complete
the Services are in Consultant’s sole discretion and control. Consultant agrees to provide his own equipment, tools, and other materials at his own expense; however, the Company will make its facilities and equipment available to Consultant
when necessary. 
  

	2.	 Compensation. 

 

	 	2.1.	 The Company is providing a one time payment of $100.00 for the services to be provided hereunder.

  

	 	2.2.	 The Company will reimburse Consultant for all reasonable expenses, including non-local travel, incurred by Consultant in performing the Services pursuant to this Agreement, provided that Consultant receives written consent from the Company’s President or Chief Financial Officer prior to
incurring any such expenses that exceed $1,000 in any calendar month and submits receipts for such expenses to the Company in accordance with Company policy 

 DESIGN THERAPEUTICS, INC. 

FIRST AMENDMENT TO CONSULTING AGREEMENT 

THIS FIRST AMENDMENT TO CONSULTING AGREEMENT (“Amendment”) is made this 1st day of June, 2018, by DESIGN
THERAPEUTICS, INC. and ASEEM Z. ANSARI, PhD, parties to that certain Consulting Agreement dated December 27, 2017 (“Agreement”). 

1. Exhibit A to the Agreement, entitled Services and Compensation, is amended to read as follows: 

 

	 	“1.	 Services. The Services shall include, but shall not be limited to, the following operational activities,
as requested by the Company: 

  

	 	•	 	 Remote and in-person consulting services regarding molecules that
modulate gene expression for commercial applications, including but not limited to human therapeutics. 

  

	 	2.	 Compensation. 

 

	 	2.1.	 The Company is providing payments totaling $40,100.00 for the Services to be provided hereunder.

  

	 	2.2	 The Company will reimburse Consultant for all reasonable expenses incurred by Consultant in performing the
Services pursuant to this Agreement, including nonlocal travel expenses and living expenses associated with any extended period in which Consultant provides in-person consulting services, provided that
Consultant receives written consent from the Company’s Chief Business Officer or Chief Financial Officer prior to incurring such expenses and, as requested, submits receipts for such expenses to the Company in accordance with Company
policy.” 

 2. Except as set forth in this Amendment, the Agreement is unaffected and shall continue in full force
and effect in accordance with its terms. If there is any conflict between this Amendment and the Agreement, the terms of this Amendment shall prevail. 

[Signature Page Follows] 

  
 1 of 2 

 IN WITNESS WHEREOF, the parties hereto have executed this First Amendment to Consulting
Agreement as of the date first written above. 
  

									
	CONSULTANT	 		 	DESIGN THERAPEUTICS, INC.
					
	By:	 	 /s/ Aseem Z. Ansari
	 		 	By:	 	 /s/ Pratik Shah

					
	Name:	 	Aseem Z. Ansari	 		 	Name:	 	Pratik Shah
	Title:	 	Consultant	 		 	Title:	 	Executive Chair
			
	Address for Notice:	 		 	Address for Notice:
			
	  
	 		 	 991C Lomas Santa Fe #436

	  
	 		 	 Solana Beach, CA 92075

 [SIGNATURE PAGE TO FIRST AMENDMENT TO CONSULTING AGREEMENT] 

  
 2 of 2 

 DESIGN THERAPEUTICS, INC. 

SECOND AMENDMENT TO CONSULTING AGREEMENT 

THIS SECOND AMENDMENT TO CONSULTING AGREEMENT (“Amendment”) is made this 1st day of October, 2020, by DESIGN
THERAPEUTICS, INC. and ASEEM Z. ANSARI, PhD, parties to that certain Consulting Agreement dated December 27, 2017 (“Agreement”). 

1. Exhibit A to the Agreement, entitled Services and Compensation, is amended to read as follows: 

 

	 	“1.	 Services. The Services shall include, but shall not be limited to, the following operational activities,
as requested by the Company: 

  

	 	•	 	 Remote and in-person consulting services regarding molecules that
modulate gene expression for commercial applications, including but not limited to human therapeutics. 

  

	 	•	 	 Oversight of the activities of the Associate Director of Discovery and the Discovery Biology group.

 For so long as the Company is paying to Consultant the consideration described in Section 2.2
below, Consultant agrees to provide eight hours per week providing Services to the Company unless otherwise agreed in writing by Consultant and the Company. 
  

	 	2.	 Compensation. 

 

	 	2.1.	 The Company and Consultant acknowledge and agree that the Company has previously paid $40,100.00 for Services
provided hereunder. 

  

	 	2.2.	 Commencing on October 1st, 2020 and through the
consummation of an initial public offering by the Company (or such period determined in the sole discretion of the Board of Directors of the Company), the Company shall pay to Consultant monthly payments of $15,000.00 for the Services provided
hereunder. 

  

	 	2.3	 The Company will reimburse Consultant for all reasonable expenses incurred by Consultant in performing the
Services pursuant to this Agreement, including nonlocal travel expenses and living expenses associated with any extended period in which Consultant provides in-person consulting services, provided that
Consultant receives written consent from the Company’s Chief Business Officer or Chief Executive Officer or Executive Chair prior to incurring such expenses and, as requested, submits receipts for such expenses to the Company in accordance with
Company policy.” 

  
 1 of 3 

 2. Except as set forth in this Amendment, the Agreement is unaffected and shall continue in
full force and effect in accordance with its terms. If there is any conflict between this Amendment and the Agreement, the terms of this Amendment shall prevail. 

[Signature Page Follows] 

  
 2 of 3 

 IN WITNESS WHEREOF, the parties hereto have executed this Second Amendment to Consulting
Agreement as of the date first written above. 
  

									
	CONSULTANT	 		 	DESIGN THERAPEUTICS, INC.
					
	By:	 	 /s/ Aseem Z. Ansari
	 		 	By:	 	 /s/ Pratik Shah

									
					
	Name:	 	Aseem Z. Ansari	 		 	Name:	 	Pratik Shah
	Title:	 	Consultant	 		 	Title:	 	Executive Chair
			
	Address for Notice:	 		 	Address for Notice:
				
		 		 		 	991C Lomas Santa Fe #436
		 		 		 	Solana Beach, CA 92075

  
  
  

 
  

[SIGNATURE PAGE TO SECOND AMENDMENT TO 

CONSULTING AGREEMENT] 

  
 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]